DNAPrint genomics Ticker Symbol Changing to 'DNAG'

DNAPrint genomics Ticker Symbol Changing to 'DNAG' 


SARASOTA, Fla., July 11  /PRNewswire-FirstCall/ -- DNAPrint genomics, Inc.
(OTC:DNAP) (BULLETIN BOARD: DNAP)  today announced that commencing with the
opening of the market on Tuesday, July 12, 2005, the Company's Common Stock
will begin trading on the Over-the-Counter Bulletin Board under the symbol
"DNAG."

The change of the symbol is the result of a stock consolidation approved by
shareholders and the Board of Directors that also becomes effective the same
day.

About DNAPrint genomics, Inc.

DNAPrint genomics, Inc. ( http://www.dnaprint.com/ ) is a developer of
genomics-based products and services focused on drug development,
pharmacogenomic diagnostic tests, forensics technology and consumer genetic
tests. The Company's first theranostic product (drug/test combination) is PT-
401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia
in renal dialysis patients (end stage renal disease). Currently in pre-
clinical development, PT-401 will be targeted to patients with a genetic
profile indicating their propensity to have the best clinical response.

   Company Contact:
   Richard Gabriel
   CEO and President
   941-366-3400
        -or-
   Ron Stabiner
   The Wall Street Group, Inc.
   212-888-4848


DATASOURCE: DNAPrint genomics



CONTACT:  Richard Gabriel, CEO and President, DNAPrint genomics,

[phone]; or Ron Stabiner, The Wall Street Group, Inc.,

[phone], for DNAPrint genomics



Web site:  http://www.dnaprint.com/ 

Copyright